Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/245439
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial |
Autor: | Koller, Dora; Almenara, Susana; Mejía, Gina; Saiz-Rodríguez, Miriam; Zubiaur, Pablo; Román, Manuel; Ochoa, Dolores; Wojnicz, Aneta; Martín, Samuel; Romero-Palacián, Daniel; Navares-Gómez, Marcos; Abad-Santos, Francisco | Palabras clave: | Aripiprazole Cardiovascular effects Olanzapine Pharmacogenetics Safety |
Fecha de publicación: | ene-2021 | Editor: | John Wiley & Sons | Citación: | Human Psychopharmacology - Clinical and Experimental 36(1): 1-12 (2021) | Resumen: | [Objective] To assess adverse events (AEs) and safety of aripiprazole (ARI) and olanzapine (OLA) treatment. [Methods] Twenty-four healthy volunteers receiving five daily oral doses of 10 mg ARI and 5 mg OLA in a crossover clinical trial were genotyped for 46 polymorphisms in 14 genes by qPCR. Drug plasma concentrations were measured by high-performance liquid chromatography tandem mass spectrometry. Blood pressure (BP) and 12-lead electrocardiogram were measured in supine position. AEs were also recorded. [Results] ARI decreased diastolic BP on the first day and decreased QTc on the third and fifth day. OLA had a systolic and diastolic BP, heart rate and QTc lowering effect on the first day. Polymorphisms in ADRA2A, COMT, DRD3 and HTR2A genes were significantly associated to these changes. The most frequent adverse drug reactions (ADRs) to ARI were somnolence, headache, insomnia, dizziness, restlessness, palpitations, akathisia and nausea while were somnolence, dizziness, asthenia, constipation, dry mouth, headache and nausea to OLA. Additionally, HTR2A, HTR2C, DRD2, DRD3, OPRM1, UGT1A1 and CYP1A2 polymorphisms had a role in the development of ADRs. [Conclusions] OLA induced more cardiovascular changes; however, more ADRs were registered to ARI. In addition, some polymorphisms may explain the difference in the incidence of these effects among subjects. | Versión del editor: | https://doi.org/10.1002/hup.2761 | URI: | http://hdl.handle.net/10261/245439 | DOI: | 10.1002/hup.2761 | ISSN: | 0885-6222 | E-ISSN: | 1099-1077 | Referencias: | Koller, Dora; Almenara, Susana; Mejía, Gina; Saiz-Rodríguez, Miriam; Zubiaur, Pablo; Román, Manuel; Ochoa, Dolores; Wojnicz, Aneta; Martín, Samuel; Romero-Palacián, Daniel; Navares-Gómez, Marcos; Abad-Santos, Francisco (2021) "Dataset related to article: Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial [Dataset]", http://dx.doi.org/10.20350/digitalCSIC/13929 |
Aparece en las colecciones: | (IIBM) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
10
checked on 08-may-2024
WEB OF SCIENCETM
Citations
10
checked on 23-feb-2024
Page view(s)
75
checked on 18-may-2024
Download(s)
15
checked on 18-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.